Apoplex Medical Technologies

Executive Summary

Apoplex Medical Technologies is a Munich-based private medical device company developing automated rhythm analysis solutions for stroke units. Its SRA® system, in clinical use since 2018, enhances atrial fibrillation detection and reduces unnecessary long-term ECGs, addressing a critical need in stroke care. The company appears to be early-stage with limited public financial data, no disclosed funding or valuation, and likely operates with minimal external capital. Its technology has shown early adoption but commercial traction and scalability remain unproven. Apoplex's success hinges on expanding its installed base, securing regulatory endorsements, and generating clinical evidence to drive broader adoption in Germany and potentially the EU.

Upcoming Catalysts (preview)

• Q3 2026Publication of new clinical study results demonstrating SRA efficacy in larger stroke unit populations60% success
• Q2 2026CE mark renewal or expansion for next-generation SRA product70% success
• Q4 2026Partnership with a major hospital group or distributor in Germany or EU50% success